Clinical trial
A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin
NCT00508924 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin
- Lead sponsor
- Tanabe Pharma Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2005
- Completion date
- October 31, 2006
- Enrollment
- 140 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.